Vedolizumab and Anti-Tumour Necrosis Factor α Real-World Outcomes in Biologic-Naïve Inflammatory Bowel Disease Patients: Results from the EVOLVE StudyBrian Bressler, Gerassimos J. Mantzaris, Anthie Gatopoulou et al.|Journal of Crohn s and Colitis|2021Cited by 148
638 Clinical Effectiveness of First-Line Anti-TNF Therapies and Second-Line Anti-TNF Therapy Post-Vedolizumab Discontinuation in Patients With Ulcerative Colitis or Crohn's DiseaseBrian Bressler, Gerassimos J. Mantzaris, Andrés Yarur et al.|The American Journal of Gastroenterology|2019Cited by 6
Real-world Clinical Effectiveness and Safety of Vedolizumab and Adalimumab in Biologic-naive Patients With Crohn’s DiseaseAndrés Yarur, Gerassimos J. Mantzaris, Pravin Kamble et al.|Journal of Clinical Gastroenterology|2024Cited by 3